Gates rounds up $94M for late-stage R&D work; Agios leaps into the clinic;

@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | Follow @FierceBiotech

@JohnCFierce: Some folks might want to adjust their timelines on ARN-509. PhIII is coming. Item | Follow @JohnCFierce

@DamianFierce: Thanks to everyone cheering my trip to FierceBiotech! | Follow @DamianFierce

> The Bill & Melinda Gates Foundation has joined hands with JPMorgan Chase and a group of investors to form a $94 million fund to back late-stage work on new treatments for a slate of killers like malaria, tuberculosis and HIV. Report

> Agios Pharmaceuticals ($AGIO), which pulled off one of this year's hottest IPOs without any human data on its drugs, has dosed the first patient in a Phase I trial of AG-221. Story

> Sequenom says it is pondering the sale of its genetic analysis unit. Story | FierceMedicalDevices' take

Medical Device News

@FierceMedDev: At AdvaMed, European regulations are on many CEOs' minds. Editor's corner | Follow @FierceMedDev

@MarkHFierce: The debt ceiling/budget fight has given an opening to device tax opponents. They hope for a repeal before year-end. More | Follow @MarkHFierce

@MichaelGFierce: Alnylam heralds positive results for RNAi amyloidosis drug. Story | Follow @MichaelGFierce

> Edwards wins FDA nod to expand Sapien label. Story

> Federal debt ceiling fight opens window for device tax opponents. Report

> Medtronic's tech halves atrial fibrillation risk. More

Pharma News

@FiercePharma: Top story on our website this A.M.: Who are the richest biopharma execs? Not all the usual suspects. Article | Follow @FiercePharma

> GlaxoSmithKline's China sales set for 30% hit, analysts figure. More

> Servier offers $483M to buy out other Egis shareholders. Story

> Pfizer rolls out digital reps in U.K., hoping for access to primary-care docs. Article

Pharma Manufacturing News

@EricPFierce: After sales of Bydureon came up short, Bristol-Myers, AstraZeneca report manufacturing has too. Article | Follow @EricPFierce

> FDA warns Agila plant over torn gloves. Story

> Pharma squares off against compounders in lobbying fight. News

> J&J wins a bright spot after string of recalls. More

> FDA beefs up Indian staff in face of serious problems. Story

> U.K., Australia gather FDA intel on Ranbaxy ban. Report

Biotech Research News

@EmilyMFierce: $3.7M NIH program to fund biomedical research training. Item | Follow @EmilyMFierce

> Stem cell therapy protects vision in preclinical retinal disease study. More

> Pre-leukemia drug shows brain tumor regression in mice. News

> Stem cell reprogramming made easier by removing one protein. Report

> New compound kills tuberculosis bacterium in lab tests. Story

> NIH launches $45M Alzheimer's research effort, awards funds to 3 preclinical studies. Article

And Finally… Investigators at Johns Hopkins say that a repurposed drug already approved at the FDA was able to wipe out brain tumor cells in IDH1 mutant gliomas taken from humans. Release

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.